Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Complementary and Integrative Medicine

Editor-in-Chief: Lui, Edmund

Ed. by Ko, Robert / Leung, Kelvin Sze-Yin / Saunders, Paul / Suntres, PH. D., Zacharias

CiteScore 2017: 1.41

SCImago Journal Rank (SJR) 2017: 0.472
Source Normalized Impact per Paper (SNIP) 2017: 0.564

See all formats and pricing
More options …

The aqueous tuber extract of Pueraria tuberosa (Willd.) D.C. caused cytotoxic effect on HT 29 cell lines with down regulation of nuclear factor-kappa B (NF-κB)

Adeolu Alex Adedapo
  • Corresponding author
  • Department of Veterinary Physiology, Biochemistry and Pharmacology, Faculty of Veterinary Medicine, University of Ibadan, Ibadan, Nigeria
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Olusegun A Fagbohun
  • Department of Veterinary Microbiology, Faculty of Veterinary Medicine, University of Ibadan, Ibadan, Nigeria
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Christianah Dawurung
  • Department of Veterinary Physiology and Pharmacology, Faculty of Veterinary Medicine, University of Jos, Jos, Nigeria
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Ademola Adetokunbo Oyagbemi
  • Department of Veterinary Physiology, Biochemistry and Pharmacology, Faculty of Veterinary Medicine, University of Ibadan, Ibadan, Nigeria
  • Department of Veterinary Physiology and Pharmacology, Faculty of Veterinary Medicine, University of Jos, Jos, Nigeria
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Temidayo Olutayo Omobowale
  • Department of Veterinary Medicine, Faculty of Veterinary Medicine, University of Ibadan, Ibadan, Nigeria
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Momoh Audu Yakubu
  • Department of Environmental and Interdisciplinary Sciences, College of Science, Engineering and Technolog, Texas Southern University, Houston, TX 77074, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2017-10-18 | DOI: https://doi.org/10.1515/jcim-2016-0119



Pueraria tuberosa (Willd) D.C. (Fabaceae) tubers are already used in traditional medicine by Ayurvedic physicians for the management of fertility disorders, general weakness, and also as anti-ageing therapies. Other known pharmacological properties include: anti-hyperglycemics, hepatoprotective, anti-hyperlipidemic, diuretic, nutritive, and anti-fertility agents in male rats.


The anti-proliferative effect of the aqueous tuberous root extract of Pueraria tuberosa on vascular smooth muscle cells (VSMCs) and Human Colorectal Adenocarcinoma Cell lines (HT-29) was investigated using the Cell Titer 96 MTT Proliferation Assay where the viable cells were seeded at a density of 5 × 104 (100 µL/well). For VSMC, log concentrations of the extract at 200 and 800 µg/mL were added and incubated for 24 and 48 h time points. Incubation of the extract in the presence of vascular endothelial growth factor (VEGF) and ET-1 was also conducted at different times. Concentrations of the extract (200, 400 and 700 µg/mL) were also added and incubated with the HT 29 cell lines for 24, 48 and 72 h time points. The effect of the tuber aqueous extract of the plant on nuclear factor-κB (NF-κB) expression after 2 h was also carried out using immunoblotting technique.


The result showed that after 24 h, the effect of the extract in the presence of the mitogens and on the VSMC was more of proliferation. However, at 48 h, the 200 µg/mL dose, both alone and in the presence of VEGF caused 11.1% and 25.9% decreases respectively, in cell proliferation. In the HT 29 cytotoxic study the 200 µg/mL concentration caused the greatest cytotoxic effect at 77.1% cell inhibition followed by 400 µg/mL concentration at 71.4% after 72 h. The immunoblotting assay showed a down regulation of NF-κB expressions with 0.7 µg/mL concentration showing the greatest effect. NF-κB, a pro-inflammatory agent is increasingly recognized as a crucial player in many steps of cancer initiation and progression.


It could therefore be concluded that the aqueous root extract of Pueraria tuberosa possesses cytotoxic effect and could serve as a lead compound for anticancer and anti-inflammatory agents.

Keywords: anticancer; HT 29; inflammation; NF-κB; Pueraria tuberosa; VSMC


  • [1]

    Mathers C, Boschi-Pinto C, Lopez A, Murray C. Cancer incidence, mortality and survival by site for 14 regions of the world. Lyon, France: World Health Organization; 2001.Google Scholar

  • [2]

    Lage H, Duarte N, Coburger C, Hilgeroth A, Ferreira MJU. Antitumor activity of terpenoids against classical and atypical multidrug resistant cancer cells. Phytomed. 2010;17:441–48.CrossrefGoogle Scholar

  • [3]

    Carter S, Livingston R. Principle of cancer chemotherapy. In: Carter S, Glatstein E, Livingston R, editors. principles of cancer treatment. New York, NY: McGraw-Hill; 1982. p. 95–110.Google Scholar

  • [4]

    Cragg M, Newman D. Natural product drugs discovery in next millennium. Frederick, MD: National Cancer Institute; 2001.Google Scholar

  • [5]

    Stevigny C, Bailly C, Quetin-Leclercq J. Cytotoxic and antitumor potentialities of aporphinoid alkaloids. Curr Med Chem—Anti-Cancer Agents. 2005;5:173–82.CrossrefGoogle Scholar

  • [6]

    Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Natural Prod. 2007;70:461–77.Web of ScienceCrossrefGoogle Scholar

  • [7]

    Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Natural Prod. 2012;75:311–35.Web of ScienceCrossrefGoogle Scholar

  • [8]

    Pandey GS, Chunekar KC, Vidari K, editors. Bhav Prakash Nighantu, vol. 1. Varanasi: Chaukambha Vidya Bhavan, 1998:388–89.Google Scholar

  • [9]

    Tripathi YB, Nagwani S, Mishra P, Jha A, Rai SP. Protective effect of Pueraria tuberosa DC. embedded biscuit on cisplatin-induced nephrotoxicity in mice. J Nat Med. 2012;66:109–18.PubMedCrossrefWeb of ScienceGoogle Scholar

  • [10]

    Handa SS, Kaul MK. Recent development of some natural products. In: Handa SS, Kaul MK, editors. Supplement to cultivation and utilization of medical plants. Jammu-Tawi: CSIR, RPL; 1996. p. 53–96.Google Scholar

  • [11]

    Hsu FL, Liu IM, Kuo DH, Chen WC, Su HC, Cheng JT. Antihyperglycemic effect of puerarin in streptozotocin-induced diabetic rats. J Nat Prod. 2003;66:788–92.CrossrefPubMedGoogle Scholar

  • [12]

    Gupta RS, Sharma R, Sharma A. Antifertility effects of Pueraria tuberosa root extract in male rats. Pharm Biol. 2004;42:3–9.Google Scholar

  • [13]

    Tanwar YS, Goyal S, Ramawat KG. Hypolipidemic effects of tubers of Indian Kudzu (Pueraria tuberosa). J Herb Med Toxicol. 2008;2:21–25.Google Scholar

  • [14]

    Joshi BS, Kamat VN. Tuberosin, a new pterocarpan from Pueraria tuberosa DC. J Chem Soc Perkin. 1993;9:907–11.Google Scholar

  • [15]

    Khan RA, Agarwal PK, Kapil RS. Puetuberosanol an epoxychalcanol from Pueraria tuberosa. Phytochem. 1996;42:42–44.Google Scholar

  • [16]

    Mizuno Y, Jacob RF, Mason RP. Inflammation and the development of atherosclerosis—effects of lipid lowering therapy. J Atheroscler Thromb. 2011;18:351–58.PubMedCrossrefGoogle Scholar

  • [17]

    Bagad AS, Joseph JA, Bhaskaran N, Agarwal A. Comparative evaluation of anti-inflammatory activity of Curcuminoids, Turmerones, and aqueous extract of Curcuma longa. Adv Pharmacol Sc. 2013;Article ID 805756:7 pages.Google Scholar

  • [18]

    Pandey N, Chaurasia JK, Tiwari OP, Tripathi YB. Antioxidant properties of different fractions of tubers from Pueraria tuberosa Linn. Food Chem. 2007;105:19–22.Web of ScienceGoogle Scholar

  • [19]

    Van De Loosdrecht AA, Beelen RH, Ossenkoppele GJ, Broekhoven MG, Lansenhuijsen MM. A tetrazolium-based colometric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods. 1994;174:311–20.CrossrefGoogle Scholar

  • [20]

    Chiong M, Cartes-Saavedra B, Norambuena-Soto I, Mondaca-Ruff D, Morales PE, Garcia-Miquel M, et al. Mitochondrial metabolism and the control of vascular smooth muscle cell proliferation. Front Cell Dev Biol. 2014;2:72 pages.PubMedGoogle Scholar

  • [21]

    Ho-Tin-Noe B, Le Dall J, Gomez D, Louedec L, Vranclex R, El-Bouchtaoui M, et al. Early atheroma-derived agonists of peroxisome proliferator-activated receptor-gamma trigger intramedial angiogenesis in a smooth muscle cell-dependent manner. Circ Res. 2011;109:1003–14.CrossrefWeb of ScienceGoogle Scholar

  • [22]

    Ragolia L, Palaia T, Paric E, Maesaka JK. Prostaglandin D2 synthase inhibits the exaggerated growth phenotype of spontaneously hypertensive rat vascular smooth muscle cells. J Biol Chem. 2003;278:22175–81.CrossrefPubMedGoogle Scholar

  • [23]

    Rudijanto A. The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis. Acta Med Indones. 2007;39:86–93.PubMedGoogle Scholar

  • [24]

    Freise C, Querfeld U. The lignan (+)-episesamin interferes with TNF-α-induced activation of VSMC via diminished activation of NF-κB, ERK1/2 and AKT and decreased activity of gelatinases. Acta Physiol (Oxf). 2015;213:642–52.PubMedCrossrefGoogle Scholar

  • [25]

    Lusis AJ. Atherosclerosis. Nature. 2000;407:233–41.CrossrefPubMedGoogle Scholar

  • [26]

    Roberts E, Cossigny DAF, Quan GMY. The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton. Prostate Cancer Vol. 2013;Article ID 418340: 8 pages. Hindawi Publications.Google Scholar

  • [27]

    Li Q, Verma IM. NF-kappa B regulation in the immune system. Nat Rev Immunol. 2002;2:725–34.PubMedCrossrefGoogle Scholar

  • [28]

    Staudt LM, Karin M. The nuclear factor NF-kB pathway in inflammation. Cold Spring Harb Perspect Biol. 2009;1:a001651.CrossrefGoogle Scholar

  • [29]

    Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappa B pathway in the treatment of inflammation and cancer. J Clin Invest. 2001;107:135–42.CrossrefPubMedGoogle Scholar

  • [30]

    Karin M, Cao Y, Greten FR, Li ZW. NF-kappa B in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301–10.CrossrefPubMedGoogle Scholar

About the article

Received: 2016-10-15

Accepted: 2017-07-11

Published Online: 2017-10-18

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: This study was supported with a grant (TETFUND/DESS/NRF/UI IBADAN/STI/VOL. 1/B2.20.11) received from the National Research Foundation of the Tertiary Education Trust Fund (TETFUND), Nigeria.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Citation Information: Journal of Complementary and Integrative Medicine, 20160119, ISSN (Online) 1553-3840, DOI: https://doi.org/10.1515/jcim-2016-0119.

Export Citation

© 2017 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in